NPRRF.US Nipro Corp
- Market cap
- -
- P/E
- 23.5x
- P/B
- 0.72x
- ROE
- 5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is NPRRF.US undervalued?
Graham numberThe Graham number of Nipro Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nipro Corp fundamental analysis
No fundamental analysis for Nipro Corp yet.
Nipro Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nipro Corp
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company's Pharmaceutical business provides pharmaceutical combination products, including dual chamber ba…
Full company profileNipro Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nipro Corp annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | 456B | 495B | 545B | 587B | 645B | 661B | 670B |
| Gross Profit | - | - | - | 139B | 149B | 163B | 171B | 191B | 208B | 216B |
| Operating Income | - | - | - | 27.6B | 23.9B | 17.7B | 22.3B | 26.6B | 37.6B | 30.8B |
| EBITDA | - | - | - | - | - | 70.0B | 84.6B | 92.6B | 103B | 39.7B |
| Net Income | - | - | - | 14.2B | 13.5B | 4.57B | 11.1B | 5.11B | 13.5B | 15.4B |
| EPS | - | - | - | 87 | 82 | 28 | 68 | 31 | 83 | 94 |
| Balance Sheet | ||||||||||
| Total Assets | - | - | - | 854B | 930B | 1.03T | 1.11T | 1.17T | 1.21T | 1.22T |
| Total Liabilities | - | - | - | 680B | 730B | 785B | 840B | 859B | 879B | 877B |
| Shareholders' Equity | - | - | - | 174B | 200B | 242B | 270B | 312B | 274B | 283B |
| Cash & Short-term Investments | - | - | - | 90.3B | 95.3B | 89.7B | 99.7B | 107B | 97.8B | 105B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 41.0B | 41.4B | 37.2B | 66.1B | 68.2B | 10.4B | 72.9B | 68.5B | 54.7B | - |
| Capital Expenditure | 62.4B | 56.0B | 57.9B | 51.2B | 79.8B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | 66.1B | 68.2B | 10.4B | 72.9B | 68.5B | 54.7B | - |
| Ratios | ||||||||||
| ROE | - | - | - | 8.2% | 6.7% | 1.9% | 4.1% | 1.6% | 4.9% | 5.4% |
| ROA | - | - | - | 1.7% | 1.4% | 0.4% | 1.0% | 0.4% | 1.1% | 1.3% |
| Net Profit Margin | - | - | - | 3.1% | 2.7% | 0.8% | 1.9% | 0.8% | 2.0% | 2.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nipro Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 27.9%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 3.76B | 23 | 27.9% |
| 2025 | USD 4.41B | 27 | 86.2% |
| 2024 | USD 3.03B | 19 | 27.2% |
| 2023 | USD 4.25B | 26 | 92.9% |
| 2022 | USD 5.22B | 32 | 38.8% |
| 2021 | USD 1.72B | 11 | 12.1% |
| 2020 | USD 3.66B | - | - |
| 2019 | USD 4.95B | - | - |
| 2018 | USD 6.48B | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 28, 2011.
Who owns Nipro Corp
- Insiders 13.71%
- Institutions 23.78%
- Public & others 62.51%
- Free float 141M
Nipro Corp company profile
- Company name
- Nipro Corp
- Ticker
- NPRRF.US
- Exchange
- USA Stocks
- Sector
- Real Estate
- Industry
- REIT - Residential
- Employees
- 36,259
- Fiscal year end
- March
- Address
- 3-9-3 Honjo-nishi, Osaka, Japan, 531-8510
- Phone
- 81 6 6372 2331
- Website
- nipro.co.jp
About Nipro Corp
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company's Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services. Its Pharma Packaging business offers glass products and other comprehensive pharmaceutical packaging, such as glass vials, ampoules, and syringes; tube glass; and other parts of pharmaceutical packaging, such as rubber plugs, as well as provides glass for thermos bottles, and lighting and containers. The company also offers business management services. It serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.
Nipro Corp management
10- Mr. Yoshihiko SanoPres & Representative Director
- Mr. Takehito YogoCFO, Deputy GM of Corp. Planning Division, Mang. of Corp. Planning Dept, MD & Director · born 1968
- Mr. Akihiko YamabeMang. of Accounting Department - Corp. Planning Division
- Masanobu IwasaMang. of Bus. Devel. Department of PharmaPackaging Division & Director
- Hideto NakamuraGM of Gen. Affairs & Personnel Division, Mang. of Personnel Dept and Director
- Mr. Kiyotaka YoshiokaChief of Bus. Strategy Office, MD, Mang. of Domestic Bus. Dept and Director · born 1969
- Mr. Toshiaki MasudaChief of Gen. Research Office, MD, Mngr of Planning Dev Technology Bus. Dept & Director · born 1946
- Mr. Tsuyoshi YamazakiChief of Global Strategy Office, Mang. of the MP Glass Bus. Department, MD & Director
- Yozo SawadaMang. of Intellectual Property Department & Director
- Mitsutaka UedaDeputy GM of Medical Technology Division for Planning, Devel. & Marketing and Director